title: Five Antiretroviral Drug Class-Resistant HIV-1 in a Treatment-Naïve Patient Successfully Suppressed with Optimized Antiretroviral Drug Selection.
abstract: Transmitted HIV-1 exhibiting reduced susceptibility to protease and reverse transcriptase inhibitors is well documented but limited for integrase inhibitors and enfuvirtide. We describe here a case of transmitted 5 drug class-resistance in an antiretroviral (ARV)-naïve patient who was successfully treated based on the optimized selection of an active ARV drug regimen. The value of baseline resistance testing to determine an optimal ARV treatment regimen is highlighted in this case report.
authors.affiliation: Monogram Biosciences, South San Francisco, CA, USA.
authors.forename: Joseph M
authors.initials: JM
authors.lastname: Volpe
authors.affiliation: Dupont Circle Physicians Group, Washington, DC, USA.
authors.forename: Douglas J
authors.initials: DJ
authors.lastname: Ward
authors.affiliation: Monogram Biosciences, South San Francisco, CA, USA.
authors.forename: Laura
authors.initials: L
authors.lastname: Napolitano
authors.affiliation: Monogram Biosciences, South San Francisco, CA, USA.
authors.forename: Pham
authors.initials: P
authors.lastname: Phung
authors.affiliation: Monogram Biosciences, South San Francisco, CA, USA.
authors.forename: Jonathan
authors.initials: J
authors.lastname: Toma
authors.affiliation: Monogram Biosciences, South San Francisco, CA, USA.
authors.forename: Owen
authors.initials: O
authors.lastname: Solberg
authors.affiliation: Monogram Biosciences, South San Francisco, CA, USA petropc@labcorp.com.
authors.forename: Christos J
authors.initials: CJ
authors.lastname: Petropoulos
authors.affiliation: Monogram Biosciences, South San Francisco, CA, USA.
authors.forename: Charles M
authors.initials: CM
authors.lastname: Walworth
mesh_terms: D000328:Adult; D044966:Anti-Retroviral Agents / Q000008:administration & dosage*; D003510:Cyclohexanes / Q000008:administration & dosage; D024882:Drug Resistance, Viral; D000077560:Enfuvirtide; D015700:HIV Envelope Protein gp41 / Q000008:administration & dosage; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology*; D019428:HIV Integrase Inhibitors / Q000008:administration & dosage; D015497:HIV-1 / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D008297:Male; D000077592:Maraviroc; D010446:Peptide Fragments / Q000008:administration & dosage; D014230:Triazoles / Q000008:administration & dosage; D056189:Viral Tropism
chemical_list: D044966:Anti-Retroviral Agents; D003510:Cyclohexanes; D015700:HIV Envelope Protein gp41; D019428:HIV Integrase Inhibitors; D010446:Peptide Fragments; D014230:Triazoles; D000077560:Enfuvirtide; D000077592:Maraviroc
keywords: enfuvirtide; integrase inhibitors; maraviroc; transmitted drug resistance; tropism